Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Convertible Debt (2017 - 2023)

Neurocrine Biosciences filings provide 7 years of Convertible Debt readings, the most recent being $169.5 million for Q1 2023.

  • On a quarterly basis, Convertible Debt fell 55.12% to $169.5 million in Q1 2023 year-over-year; TTM through Mar 2023 was $169.5 million, a 55.12% decrease, with the full-year FY2021 number at $335.1 million, up 5.41% from a year prior.
  • Convertible Debt hit $169.5 million in Q1 2023 for Neurocrine Biosciences, roughly flat from $169.0 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $414.1 million in Q1 2020 to a low of $169.0 million in Q2 2022.
  • Median Convertible Debt over the past 5 years was $332.9 million (2021), compared with a mean of $329.8 million.
  • Biggest five-year swings in Convertible Debt: rose 17.3% in 2022 and later plummeted 55.12% in 2023.
  • Neurocrine Biosciences' Convertible Debt stood at $403.6 million in 2019, then decreased by 21.23% to $317.9 million in 2020, then increased by 5.41% to $335.1 million in 2021, then plummeted by 49.57% to $169.0 million in 2022, then rose by 0.3% to $169.5 million in 2023.
  • The last three reported values for Convertible Debt were $169.5 million (Q1 2023), $169.0 million (Q2 2022), and $377.7 million (Q1 2022) per Business Quant data.